HILO WAVE vs SKINVIVE in Seoul: How Are These HA Injectables Different?

The short answer: both use HA, but they are not interchangeable

HILO WAVE and SKINVIVE are both injectable hyaluronic-acid products, but that shared ingredient does not make them the same treatment. HILO WAVE’s Korean product information lists a 2.0 mL syringe with 48 mg total HA and an authorized purpose of temporarily improving adult facial wrinkles. Current US FDA information describes SKINVIVE as 12 mg/mL BDDE-crosslinked HA with 0.3% lidocaine, indicated for cheek smoothness and, after a June 2026 supplement, neck-line improvement in adults over 21.

Those are jurisdiction-specific facts, not a winner. The Korean label for a Seoul treatment must be checked directly, and neither product should be expanded to a new area because a foreign label or social post uses broader language. Two milliliters of one product is not automatically equivalent to two milliliters of the other.

Le Moir currently lists both HILO WAVE and SKINVIVE. That confirms treatment availability, not personal suitability. A useful consultation should first define the concern—facial wrinkles, cheek smoothness, dry-feeling skin, texture, volume loss, laxity, pigment or inflammation—then explain why the proposed product, amount, area and technique fit that concern.

HILO WAVE: what the official Korean product information actually says

The official product styling is HILO WAVE. Its Korean product page identifies it as a Grade 4 biomaterial graft and prosthesis, supplied as one 2.0 mL syringe containing 48 mg total hyaluronic acid. It describes high- and low-molecular-weight HA and states a Korean purpose of temporary improvement of adult facial wrinkles through physical tissue restoration.

That label language is more precise than calling it a generic ‘hydration’ or ‘glass skin’ injection. Manufacturer descriptions of comfort, duration or performance are marketing claims unless they are supported by the current instructions for use and applicable clinical evidence. In the PubMed search conducted for this guide, we did not find a peer-reviewed HILO WAVE-specific clinical trial or a direct comparison with SKINVIVE.

A general systematic review found that injectable HA studies report possible improvements in hydration and radiance, while a later meta-analysis did not find significant pooled changes in elasticity. Those findings cover different HA formulations, populations and techniques. They cannot be transferred wholesale to HILO WAVE or used to predict an individual result.

SKINVIVE: product-specific FDA evidence, with a local-label caveat

The US FDA summary describes SKINVIVE by JUVÉDERM as a sterile HA gel at 12 mg/mL, crosslinked with BDDE and containing 0.3% lidocaine. Each US retail box contains two prefilled 1.0 mL syringes. Its US indications cover intradermal cheek-smoothness treatment and, since June 2026, intradermal or subdermal treatment of neck lines in adults over 21.

SKINVIVE has product-specific controlled clinical data supporting those US indications. That is stronger product-specific evidence than we could verify for HILO WAVE, but it still does not prove that SKINVIVE is universally better, that every treated area is on-label in Korea or that the same amount suits every face. Le Moir’s physician should identify the current Korean authorization and explain the proposed area and depth before consent.

The clinic-owned photograph below shows the actual SKINVIVE box for identification only. Before treatment, ask to see the sealed product, expiry and lot, and keep a record of the total amount and treated areas. A genuine package supports product verification; it does not decide whether the product is appropriate for you.

Why there is no responsible one-line winner

No direct head-to-head trial was found for HILO WAVE versus SKINVIVE in the sources reviewed on 15 September 2026. Separate product pages and separate studies cannot be treated as a comparison trial: formula, concentration, injection layer, treated area, total volume, outcome scale and follow-up may all differ.

The phrase ‘skin booster’ is useful in conversation but is not a standardized formula or dose. HA concentration alone does not rank a product, and a larger syringe does not promise a larger or longer result. The better question is whether the product-specific evidence and current local instructions match the exact concern and area being proposed.

I would also ask what would make the physician recommend neither option. Active irritation or infection, a primarily pigment-based concern, unclear lumps from previous injections, structural volume loss or laxity may change the plan. Skincare, another treatment category, staging or simply waiting can be the more defensible answer.

• Confirm the exact product name, manufacturer, lot and expiry.
• Write down total milliliters, treated area, layer and injection method.
• Ask which current Korean indication and product-specific evidence support the plan.
• Separate texture or smoothness goals from volume, pigment and laxity goals.
• Request a follow-up route that remains usable after leaving Korea.

Safety and recovery: ‘skin quality’ still means an injection

Both plans can involve temporary redness, swelling, tenderness, bruising, itching, firmness or visible bumps. Infection, delayed inflammation, persistent nodules, asymmetry and an unsatisfactory result are less routine possibilities. Any facial HA injection also carries a rare but serious risk of unintended entry into a blood vessel, which can cause tissue injury, visual impairment, blindness or stroke.

Tell the physician about allergies, previous reactions, active skin problems, healing conditions and every prior filler, skin booster, biostimulator, thread, laser or energy treatment by date and area. The clinician should explain product-specific contraindications and aftercare from the current local instructions rather than rely on a generic booster script.

Seek urgent medical assessment for severe or escalating pain, blanching or dusky skin, a vision change, weakness, trouble speaking, trouble breathing or rapidly increasing swelling. Contact the treating clinic promptly for fever, drainage, spreading heat or redness, a firm new nodule or recovery that is moving in the wrong direction.

Does a hand injection or injector change the product decision?

A delivery method is not the medicine. Hand injection and injector-assisted plans can differ in placement, spacing and the way a clinician controls each deposit, but the device name does not turn one HA formulation into another or prove a result. Anatomy, product instructions, area, depth and the treating physician’s judgment still lead the decision.

The X-Injector image below is included because Le Moir may discuss it as one delivery option. It is not a recommendation for HILO WAVE or SKINVIVE and it is not a dosing map. Ask which method is proposed, why it fits the chosen product and area, and how the clinic adapts the plan if your skin is thin, reactive or previously treated.

A fair Seoul quote and a calmer travel plan

A fair quote should name HILO WAVE or SKINVIVE—not only ‘HA booster’—and itemize the total milliliters, treated area, injection method, VAT, aftercare and follow-up. The official pack size is not necessarily the amount a physician will recommend, and prices should not be compared unless those treatment units match.

For a short Seoul visit, schedule the consultation early and show the clinic your flight, event and photography dates. Do not assume small injection points will disappear on a fixed day. A first-time injectable immediately before a long-haul flight or important event leaves little room for review if swelling, bruising or an unexpected reaction develops.

The friendliest advice is also the simplest: choose the clearest product-specific plan, not the loudest ‘glow’ promise. If the exact label, amount, area, evidence or follow-up is vague, pause and ask for a written explanation before proceeding.